In this issue, Lee and colleagues1 present the results of the largest prospective clinical cohort study to date concerning 507 women with vulvar lichen sclerosus (VLS). The authors present evidence that poor compliance with topical corticosteroid (TCS) treatment predisposes patients to the development of vulvar cancer and scarring. They propose that initial treatment regimens should be selected using a variety of corticosteroid potencies based on the severity of signs at presentation. They also propose that maintenance treatment for VLS should be the norm, increasing or decreasing the potency of treatment as necessary. The authors recommend life-long specialist follow-up.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Cooper SM, Madnani N, Margesson L. Reduced Risk of Squamous Cell Carcinoma With Adequate Treatment of Vulvar Lichen Sclerosus. JAMA Dermatol. 2015;151(10):1059–1060. doi:10.1001/jamadermatol.2015.0644
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: